Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

Share Price is delayed by 15 minutes
Get Live Data
225.50    -3.50 (-1.53%)
Bid:
225.00
Ask:
225.50
Spread: 0.50 (0.222%)
Market Cap: £623.32m
MGAM Live PriceLast checked at - London Stock Exchange

Intraday Morgan Advanced Materials Share Chart

Strategy Update

4 Dec 2025 07:00

RNS Number : 1624K
Morgan Advanced Materials PLC
04 December 2025
 

Press Release

Morgan Advanced Materials plc

4 December 2025

Strategy Update

Unlocking our potential

Morgan Advanced Materials plc, the global leader in advanced ceramics and carbon systems for technologically demanding applications, is today holding a Strategy Update in London. Participation in the event is by invitation only for institutional analysts and investors.

Damien Caby, Chief Executive Officer and Richard Armitage, Chief Financial Officer will host the event. They will present Morgan's strategy for sustainable growth, focussing on:

Transforming our operational effectiveness to turnaround underperforming sites and improve our supply chain effectiveness

Driving stronger growth by focusing on our right to win to enhance our value proposition, strengthening partnerships, and expanding in the right areas to gain share

Maximising our portfolio through partnerships, divestments and bolt-on M&A

They will also set out an updated financial framework and re‐iterate our capital allocation priorities:

Above Market Organic Revenue Growth. We expect to achieve growth in excess of GDP

Attractive Margins. We expect to achieve adjusted operating profit margin of 12% by 2028 with sustainable adjusted operating profit margins of between 12% and 14% beyond 2028

Delivering EPS Growth. Achieving sustained growth in adjusted Earnings per Share, ahead of organic revenue growth, driven by a combination of organic growth, margin accretion, shareholder returns and M&A

Sustaining ROIC. 17% ‐ 20% ROIC

Leverage Range. 1.0x to 1.5x, or up to 2.0x adjusted EBITDA post-acquisition, utilising our strong balance sheet to fund our organic growth, and then over time deploying excess capital to fund incremental M&A or additional shareholder returns as appropriate

Dividend Cover. Shareholder dividends maintained then growing with adjusted earnings at around 2.5x cover

We intend to pause our buy-back programme as part of our focus on balance sheet resilience. The programme will be paused after the completion of the second tranche, by which time we will have purchased £20m of shares.

No new information on current year trading will be shared at the event.

Damien Caby, Chief Executive Officer, commented:

"Morgan is an exciting innovative company with distinctive capabilities and competitive advantages that give us a decisive right to win across our diverse markets. However, we have not been delivering to our ambition or to our full potential. Much of this value can be achieved through more rigorous customer focus and portfolio management. I will set out today a clear strategy focussing on unlocking the Group's potential by focussing on transformation of operational effectiveness, driving stronger growth and the maximisation of portfolio value. This will help us improve the financial performance of the group on a more sustainable basis to deliver against a revised financial framework."

The presentation will be made available at www.morganadvancedmaterials.com at 2pm today, along with a recording of the presentation that will be made available following the event.

 

For further enquiries:

Richard Armitage, CFO

Morgan Advanced Materials

01753 837 000

Nicholas Frost, Investor Relations

 

 

 

 

Nina Coad

Brunswick

0207 404 5959

 

Important notice:

This announcement contains forward-looking statements. These statements have been made in good faith based on the information available up to the time of the approval of this announcement. No assurance can be given that these expectations will prove to have been correct. By their nature, forward-looking statements involve risks, uncertainties or assumptions that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. As such, undue reliance should not be placed on forward-looking statements.

The Directors undertake no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKXLFBELLZFBD
Date   Source Headline
23rd Apr 20187:00 amRNSQ1 Trading Update
10th Apr 20183:31 pmRNSAnnual Financial Report
29th Mar 20183:47 pmRNSHolding(s) in Company
21st Mar 20184:26 pmRNSDirector/PDMR Shareholding
21st Mar 20184:12 pmRNSDirector/PDMR Shareholding
21st Mar 201810:04 amRNSHolding(s) in Company
2nd Mar 201811:22 amRNSHolding(s) in Company
1st Mar 201811:31 amRNSDirector/PDMR Shareholding
27th Feb 20187:00 amRNSFull-year results for period ended 31 Dec 2017
24th Jan 20187:00 amRNSUS tax reform
2nd Jan 201810:32 amRNSDirector/PDMR Shareholding
15th Dec 20178:00 amRNSBlock listing Interim Review
11th Dec 20177:00 amRNSAdditional US pension payment
8th Dec 20172:22 pmRNSChange of Senior Independent Director
27th Nov 201710:29 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSTrading update
26th Sep 201710:39 amRNSDirector/PDMR Shareholding
22nd Sep 20175:03 pmRNSDirector/PDMR Shareholding
5th Sep 201711:13 amRNSDirector/PDMR Shareholding
4th Sep 201712:09 pmRNSDirector/PDMR Shareholding
30th Aug 201712:31 pmRNSHolding(s) in Company
28th Jul 20177:00 amRNSHALF YEAR RESULTS FOR 6 MONTHS ENDED 30 JUNE 2017
24th Jul 201711:53 amRNSHalf year results notification
6th Jul 20173:44 pmRNSHolding(s) in Company
15th Jun 20179:39 amRNSBlock listing Interim Review
5th May 20171:52 pmRNSResult of AGM
5th May 20177:00 amRNSTrading Statement
28th Apr 20179:36 amRNSAppointment of Non-Executive Director
12th Apr 201710:53 amRNS2016 Environmental, Health and Safety Report
10th Apr 201711:01 amRNSDirector/PDMR Shareholding
4th Apr 201710:38 amRNSDirector/PDMR Shareholding
3rd Apr 20172:03 pmRNSCompletion of Disposals
31st Mar 20173:56 pmRNSDirector/PDMR Shareholding
31st Mar 20172:07 pmRNSAnnual Financial Report
6th Mar 20172:27 pmRNSDirector/PDMR Shareholding
6th Mar 20172:25 pmRNSDirector/PDMR Shareholding
6th Mar 20172:22 pmRNSDirector/PDMR Shareholding
1st Mar 20179:41 amRNSDirector/PDMR Shareholding
23rd Feb 20177:00 amRNSFull-Year Results
22nd Feb 20177:00 amRNSSale of UK Electro-Ceramics business to CeramTec
17th Feb 20177:00 amRNSSale of global Rotary business to Moog Inc
23rd Jan 201710:58 amRNSHolding(s) in Company
4th Jan 20179:51 amRNSDirector/PDMR Shareholding
15th Dec 201611:37 amRNSBlock listing Interim Review
16th Nov 20163:26 pmRNSHolding(s) in Company
7th Nov 20167:00 amRNSTrading Statement
28th Oct 20167:00 amRNSCompletion of US private placement
28th Sep 201610:49 amRNSDirector/PDMR Shareholding
28th Sep 201610:45 amRNSDirector/PDMR Shareholding
28th Sep 201610:42 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.